Tech Company Financing Transactions
EpimAb Biotherapeutics Funding Round
EpimAb Biotherapeutics, based in Shanghai, secured $25 million in investment from Oriza Ventures, 3E Bioventures and Decheng Capital.
Transaction Overview
Company Name
Announced On
4/26/2017
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series A
Investors
Proceeds Purpose
With the funding, Epimab will advance its proprietary bispecific platform technology and build a pipeline of therapeutic candidates in immuno-oncology and other areas with a high unmet medical need.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
6th Floor Building 2 Jinchuang Building 702 Zhongke Rd. Zhan 205
Shanghai, 201204
China
Shanghai, 201204
China
Phone
Website
Email Address
Not Recorded
Overview
EpimAb Biotherapeutics is a privately owned biopharmaceutical company dedicated to generating novel bi-specific antibody therapeutics based on its proprietary FIT-Ig (Fabs-In-Tandem) platform.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Chengbin Wu
Chief Marketing Officer
Bin Peng
Chief Operating Officer
Stephan Lensky
Vice President
Jerry Su
VP - Regulatory Affairs
Richard Jiang
Browse more venture capital transactions:
Prev: 4/26/2017: Sensoro venture capital transaction
Next: 4/26/2017: Doc Halo venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. VC transactions reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs